Your browser doesn't support javascript.
loading
A New Rapid-Acting Antidepressant.
Krystal, John H; Charney, Dennis S; Duman, Ronald S.
Afiliación
  • Krystal JH; Departments of Psychiatry, Neuroscience, and Psychology, Yale University, New Haven, CT 06511, USA. Electronic address: john.krystal@yale.edu.
  • Charney DS; Departments of Psychiatry, Neuroscience, and Psychology, Yale University, New Haven, CT 06511, USA.
  • Duman RS; Departments of Psychiatry, Neuroscience, and Psychology, Yale University, New Haven, CT 06511, USA.
Cell ; 181(1): 7, 2020 04 02.
Article en En | MEDLINE | ID: mdl-32243798
ABSTRACT
The discovery of the strikingly rapid and robust antidepressant effects of r/s-ketamine for the treatment of antidepressant-resistant symptoms of depression has led to new insights into the biology of antidepressants and the FDA approval of its s-isomer, Esketamine (Spravato), the first mechanistically new treatment for depression in over 60 years. To view this Bench to Bedside, open or download the PDF.
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Aprobación de Drogas / Receptores de N-Metil-D-Aspartato / Trastorno Depresivo Resistente al Tratamiento / Ketamina / Antidepresivos Límite: Humans Idioma: En Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Aprobación de Drogas / Receptores de N-Metil-D-Aspartato / Trastorno Depresivo Resistente al Tratamiento / Ketamina / Antidepresivos Límite: Humans Idioma: En Año: 2020 Tipo del documento: Article